Results 181 to 190 of about 553,186 (259)

Review of Progress of AI in Biomimetics: From Biological Patterns to Closed-Loop Discovery. [PDF]

Biomimetics (Basel)
Hu Z, Hong H, Lin T.
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Pre-analytical stability of blood samples transported by drone versus ground: a pilot study. [PDF]

Pract Lab Med
Brionne M, Peyro-Saint-Paul L, Dutheil JJ, Vivien D, Legros H, Le Hello S, Morello R.   +6 more
europepmc   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Tryptophanase disruption promotes insect-bacterium mutualism. [PDF]

Nat Microbiol
Wang Y, Moriyama M, Koga R, Oguchi K, Hosokawa T, Takai H, Shigenobu S, Nikoh N, Fukatsu T.   +8 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Performance evaluation of biological safety cabinets: a real-world analysis. [PDF]

Front Bioeng Biotechnol
Song T, Yin S, Liu Z, Xue X, Li Y, Li Y, Zhang X, Qiao X, Wu C, Zhang H, Jia R, Liu X, Sun Z, Yao W, Zhang B, Xu F, Tian Y, Tian J.   +17 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Aflatoxin health risk in the feed source: Integrated strategies for feed safety and sustainable One Health. [PDF]

One Health
Sharifi SD, Ghaemmaghami SS, Rouhanipour H, Najafi A, Rasi HM, Baeelashaki R.   +5 more
europepmc   +1 more source